# GLP-1 Drugs Show Promise for Binge Eating Disorder
Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) appear to reduce binge eating episodes in people with binge eating disorder (BED), according to emerging research. These GLP-1 and GLP-1/GIP receptor agonist drugs, initially developed for type 2 diabetes and weight loss, work by slowing stomach emptying and increasing feelings of fullness.
BED affects roughly 2.8 million American adults and involves recurrent episodes of eating large quantities of food accompanied by loss of control. Unlike other eating disorders, people with BED don't typically purge afterward, but the condition carries serious health consequences including obesity, depression, and metabolic problems.
Several clinical trials have examined these medications' effects on BED specifically. In studies, patients taking GLP-1 drugs reported fewer binge eating episodes per week and greater control over their eating behavior compared to placebo groups. Researchers theorize the medications work partly through appetite suppression and partly through effects on brain regions that regulate reward and impulse control.
Psychiatrist and eating disorder specialists note that GLP-1 drugs address a distinct aspect of BED compared to traditional treatments. Cognitive behavioral therapy (CBT) remains the gold standard first-line treatment for BED, helping people identify triggers and develop coping strategies. Antidepressants like topiramate have shown modest benefits in some patients.
The emerging data suggests GLP-1 medications could complement existing therapies rather than replace them. However, experts caution that these drugs are not approved by the FDA specifically for BED treatment, and long-term safety data for eating disorder populations remains limited.
Access and cost present barriers. Many insurance plans don